Yvonne Greenstreet is Chief Executive Officer of Alnylam Pharmaceuticals, Inc. (ALNY). The company reported total compensation of $14,867,600 for fiscal year 2025.
| Salary | $1,404,200 |
|---|---|
| Bonus | $0 |
| Stock awards | $5,512,500 |
| Option awards | $4,363,380 |
| Non-equity incentive plan | $3,562,500 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $25,020 |
| Total | $14,867,600 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Alnylam Pharmaceuticals, Inc. filed April 6, 2026, accession 0001628280-26-023923.
| Peer-group chief executive median | $20,538,239 |
|---|---|
| Difference from that median | $-5,670,639 |
| Percentile within the disclosed peer group | 20th |
| Peers with a disclosed figure | 10 |
Medians and percentiles are computed across the peer group Alnylam Pharmaceuticals, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Yvonne Greenstreet this page | Chief Executive Officer | $14,867,600 |
| Jeffrey Poulton | Executive Vice President, Chief Financial Officer | $6,863,800 |
| Bryan Supran | Executive Vice President, Chief Legal Officer and Secretary | $6,846,350 |
| Pushkal Garg | Executive Vice President, Chief Research and Development Officer | $6,490,500 |
| Tolga Tanguler | Executive Vice President, Chief Commercial Officer | $6,129,020 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Alnylam Pharmaceuticals, Inc. compensation brief.
Yvonne Greenstreet's compensation sits inside Alnylam Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.